Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025

Core Insights - Akebia Therapeutics is set to present data on Vafseo (vadadustat) at the American Society of Nephrology Kidney Week 2025, highlighting ongoing real-world studies and insights into its clinical benefits and dosing [1][2][3] Company Overview - Akebia Therapeutics, Inc. is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, founded in 2007 and headquartered in Cambridge, Massachusetts [5] - Vafseo (vadadustat) is a once-daily oral medication approved for treating anemia due to chronic kidney disease (CKD) in adults on dialysis for at least three months, and it is approved in 37 countries [6][7] Clinical Studies and Presentations - Dr. Glenn M. Chertow from Stanford University will present a win odds analysis of all-cause mortality and hospitalization from the INNO2VATE trials, part of the Phase 3 clinical development program for vadadustat [2][4] - Four posters will be presented at ASN Kidney Week, focusing on dosing recommendations and ongoing real-world evidence studies, including the VOICE and VOCAL trials [2][4] Research and Development Focus - The company emphasizes the importance of generating, evaluating, and sharing data to support healthcare providers in making informed treatment decisions regarding Vafseo [3] - Akebia is actively engaged with the nephrology community to identify potential additional clinical benefits of Vafseo through various real-world evidence studies [3]